Taiho Oncology to Present Data at the 66th American Society of Hematology Annual Meeting
Data to be presented from an oral azacitidine plus cedazuridine (ASTX030) combination phase 1 open-label dose escalation and expansion trialFindings to be shared from a study analyzing real–world use patterns